

Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial

NCT07004452

Status	RECRUITING
Sponsor	China National Center for Cardiovascular Diseases
Enrollment	5,000 participants

Key Eligibility Criteria

Inclusion (4)

- Age 18-45 years;
- Clinically confirmed CAD with $\geq 50\%$ luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography;
- For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment;
- Voluntary participation with signed informed consent.

Exclusion (4)

- Heart transplant recipients;
- Severe systemic comorbidities with life expectancy < 1 year;
- Previous enrollment in other drug/device clinical trials without completing the primary endpoint observation period;
- Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).

Locations (1 total)

FuWai Hospital, Beijing, China